Thirty-day readmissions after transcatheter versus surgical mitral valve repair in high-risk patients with mitral regurgitation: Analysis of the 2014-2015 Nationwide readmissions databases.
Aged
Aged, 80 and over
Cardiac Catheterization
/ adverse effects
Databases, Factual
Female
Heart Valve Prosthesis
Heart Valve Prosthesis Implantation
/ adverse effects
Humans
Male
Middle Aged
Mitral Valve
/ diagnostic imaging
Mitral Valve Insufficiency
/ diagnostic imaging
Patient Readmission
Retrospective Studies
Risk Assessment
Risk Factors
Time Factors
Treatment Outcome
United States
MitraClip
Nationwide Readmission Database
structural heart disease
Journal
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
ISSN: 1522-726X
Titre abrégé: Catheter Cardiovasc Interv
Pays: United States
ID NLM: 100884139
Informations de publication
Date de publication:
01 09 2020
01 09 2020
Historique:
received:
26
07
2019
revised:
25
10
2019
accepted:
07
12
2019
pubmed:
24
12
2019
medline:
7
4
2021
entrez:
24
12
2019
Statut:
ppublish
Résumé
Determine the rates, reasons, predictors, and costs of 30-day readmissions following transcatheter mitral valve repair (TMVR) versus surgical mitral valve repair (SMVR) in the United States. Data on 30-day readmissions after TMVR are limited. High-risk patients with mitral regurgitation (MR) undergoing TMVR or SMVR were identified from the 2014-2015 Nationwide Readmissions Databases. Multivariable stepwise regression models were used to identify independent predictors of 30-day readmission. Risk of 30-day readmission was compared between the two groups using univariate and propensity score adjusted regression models. Among 8,912 patients undergoing mitral valve repair during 2014-2015 (national estimate 17,809), we identified 7,510 (84.7%) that underwent SMVR and 1,402 (15.3%) that underwent TMVR. Thirty-day readmission rates after SMVR and TMVR were 10.7% and 11.7%, respectively (unadjusted OR 1.11, 95% CI 0.89-1.39, p = .35). After propensity score adjustment, TMVR was associated with a lower risk of 30-day readmissions compared with SMVR (adjusted OR 0.70, 95% CI 0.51-0.95, p = .02). Heart failure and arrhythmias were the leading cardiac reasons for readmission. Anemia and fluid and electrolyte disorder were independent predictors of 30-day readmission after TMVR. Demographics, comorbidities, and length of stay were independent predictors of 30-day readmission after SMVR. One in 10 patients are readmitted within 30 days following TMVR or SMVR. Approximately half of the readmissions are for cardiac reasons. The predictors of 30-day readmission are different among patients undergoing TMVR and SMVR, but can be easily screened for to identify patients at highest risk for readmission.
Sections du résumé
OBJECTIVE
Determine the rates, reasons, predictors, and costs of 30-day readmissions following transcatheter mitral valve repair (TMVR) versus surgical mitral valve repair (SMVR) in the United States.
BACKGROUND
Data on 30-day readmissions after TMVR are limited.
METHODS
High-risk patients with mitral regurgitation (MR) undergoing TMVR or SMVR were identified from the 2014-2015 Nationwide Readmissions Databases. Multivariable stepwise regression models were used to identify independent predictors of 30-day readmission. Risk of 30-day readmission was compared between the two groups using univariate and propensity score adjusted regression models.
RESULTS
Among 8,912 patients undergoing mitral valve repair during 2014-2015 (national estimate 17,809), we identified 7,510 (84.7%) that underwent SMVR and 1,402 (15.3%) that underwent TMVR. Thirty-day readmission rates after SMVR and TMVR were 10.7% and 11.7%, respectively (unadjusted OR 1.11, 95% CI 0.89-1.39, p = .35). After propensity score adjustment, TMVR was associated with a lower risk of 30-day readmissions compared with SMVR (adjusted OR 0.70, 95% CI 0.51-0.95, p = .02). Heart failure and arrhythmias were the leading cardiac reasons for readmission. Anemia and fluid and electrolyte disorder were independent predictors of 30-day readmission after TMVR. Demographics, comorbidities, and length of stay were independent predictors of 30-day readmission after SMVR.
CONCLUSIONS
One in 10 patients are readmitted within 30 days following TMVR or SMVR. Approximately half of the readmissions are for cardiac reasons. The predictors of 30-day readmission are different among patients undergoing TMVR and SMVR, but can be easily screened for to identify patients at highest risk for readmission.
Types de publication
Comparative Study
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
664-674Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2019 Wiley Periodicals, Inc.
Références
Feldman T, Foster E, Glower DD, et al. Percutaneous repair or surgery for mitral regurgitation. N Engl J Med. 2011;364(15):1395-1406.
Samad Z, Shaw LK, Phelan M, et al. Management and outcomes in patients with moderate or severe functional mitral regurgitation and severe left ventricular dysfunction. Eur Heart J. 2015;36(40):2733-2741.
Goel SS, Bajaj N, Aggarwal B, et al. Prevalence and outcomes of unoperated patients with severe symptomatic mitral regurgitation and heart failure: comprehensive analysis to determine the potential role of MitraClip for this unmet need. J Am Coll Cardiol. 2014;63(2):185-186.
Whitlow PL, Feldman T, Pedersen WR, et al. Acute and 12-month results with catheter-based mitral valve leaflet repair: the EVEREST II (endovascular valve edge-to-edge repair) high risk study. J Am Coll Cardiol. 2012;59(2):130-139.
Feldman T, Kar S, Elmariah S, et al. Randomized comparison of percutaneous repair and surgery for mitral regurgitation: 5-year results of EVEREST II. J Am Coll Cardiol. 2015;66(25):2844-2854.
Sorajja P, Vemulapalli S, Feldman T, et al. Outcomes with transcatheter mitral valve repair in the United States: an STS/ACC TVT registry report. J Am Coll Cardiol. 2017;70(19):2315-2327.
Grover FL, Vemulapalli S, Carroll JD, et al. 2016 Annual Report of the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. J Am Coll Cardiol. 2017;69(10):1215-1230.
Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Circulation. 2017;135(25):e1159-e1195.
U.S. Centers for Medicare & Medicaid Services. Hospital Readmissions Reductions Program (HRRP) 2017. https://www.cms.gov/medicare/medicare-fee-for-service-payment/acuteinpatientpps/readmissions-reduction-program.html. Accessed May 28, 2018.
Panaich SS, Arora S, Badheka A, et al. Procedural trends, outcomes, and readmission rates pre-and post-FDA approval for MitraClip from the National Readmission Database (2013-14). Catheter Cardiovasc Interv. 2018;91(6):1171-1181.
Grasso C, Popolo Rubbio A, Capodanno D, et al. Incidence, timing, causes and predictors of early and late re-hospitalization in patients who underwent percutaneous mitral valve repair with the MitraClip system. Am J Cardiol. 2018;121(10):1253-1259.
Faridi KF, Popma JJ, Strom JB, Shen C, Choi E, Yeh RW. Utilization, in-hospital mortality, and 30-day readmission after percutaneous mitral valve repair in the United States shortly after device approval. Am J Cardiol. 2018;121(11):1365-1372.
NRD Overview. Healthcare Cost and Utilization Project (HCUP) 2017. www.hcup-us.ahrq.gov/nrdoverview.jsp. Accessed May 28, 2018.
Elixhauser Comorbidity Software, Version 3.7. 2017. www.hcup-us.ahrq.gov/toolssoftware/comorbidity/comorbidity.jsp. Accessed February 2018.
Austin SR, Wong YN, Uzzo RG, Beck JR, Egleston BL. Why summary comorbidity measures such as the Charlson comorbidity index and Elixhauser score work. Med Care. 2015;53(9):65-72.
Brooke BS, De Martino RR, Girotti M, Dimick JB, Goodney PP. Developing strategies for predicting and preventing readmissions in vascular surgery. J Vasc Surg. 2012;56(2):556-562.
Hansen LO, Young RS, Hinami K, Leung A, Williams MV. Interventions to reduce 30-day rehospitalization: a systematic review. Ann Intern Med. 2011;155(8):520-528.
Jencks SF, Williams MV, Coleman EA. Rehospitalizations among patients in the medicare fee-for-service program. N Engl J Med. 2009;360(14):1418-1428.
Maisano F, Franzen O, Baldus S, et al. Percutaneous mitral valve interventions in the real world: early and 1-year results from the ACCESS-EU, a prospective, multicenter, nonrandomized post-approval study of the MitraClip therapy in Europe. J Am Coll Cardiol. 2013;62(12):1052-1061.
Maor E, Raphael CE, Panaich SS, et al. Acute changes in left atrial pressure after MitraClip are associated with improvement in 6-minute walk distance. Circ Cardiovasc Interv. 2017;10(4):e004856.
Attizzani GF, Ohno Y, Capodanno D, et al. Extended use of percutaneous edge-to-edge mitral valve repair beyond EVEREST (endovascular valve edge-to-edge repair) criteria: 30-day and 12-month clinical and echocardiographic outcomes from the GRASP (getting reduction of mitral insufficiency by percutaneous clip implantation) registry. JACC Cardiovasc Interv. 2015;8(1 Pt A):74-82.
Grayburn PA, Foster E, Sangli C, et al. Relationship between the magnitude of reduction in mitral regurgitation severity and left ventricular and left atrial reverse remodeling after MitraClip therapy. Circulation. 2013;128(15):1667-1674.
Kang MK, Joung B, Shim CY, et al. Post-operative left atrial volume index is a predictor of the occurrence of permanent atrial fibrillation after mitral valve surgery in patients who undergo mitral valve surgery. Cardiovasc Ultrasound. 2018;16(1):5.
Arora S, Vemulapalli S, Stebbins A, et al. The prevalence and impact of atrial fibrillation on 1-year outcomes in patients undergoing transcatheter mitral valve repair: results from the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. JACC Cardiovasc Interv. 2019;12(6):569-578.
Benito-Gonzalez T, Estevez-Loureiro R, de Prado AP, et al. Incidence and prognostic implications of late bleeding events after percutaneous mitral valve repair. Int J Cardiol Heart Vasc. 2018;21:16-21.
Korber MI, Silwedel J, Friedrichs K, et al. Bleeding complications after percutaneous mitral valve repair with the MitraClip. Am J Cardiol. 2018;121(1):94-99.
Sharma A, Zhao X, Hammill BG, et al. Trends in noncardiovascular comorbidities among patients hospitalized for heart failure: insights from the get with the guidelines-heart failure registry. Circ Heart Fail. 2018;11(6):e004646.
Davis JD, Olsen MA, Bommarito K, et al. All-payer analysis of heart failure hospitalization 30-day readmission: comorbidities matter. Am J Med. 2017;130(1):93 e9-93 e28.
Coffey RM, Misra A, Barrett M, Andrews RM, Mutter R, Moy E. Congestive heart failure: who is likely to be readmitted? Med Care Res Rev. 2012;69(5):602-616.
Distelhorst K, Claussen R, Dion K, et al. Factors associated with adherence to 14-day office appointments after heart failure discharge. J Card Fail. 2018;24(6):407-411.
Silverstein MD, Qin H, Mercer SQ, Fong J, Haydar Z. Risk factors for 30-day hospital readmission in patients >/=65 years of age. Proc (Bayl Univ Med Cent). 2008;21(4):363-372.
Badhwar V, Peterson ED, Jacobs JP, et al. Longitudinal outcome of isolated mitral repair in older patients: results from 14,604 procedures performed from 1991 to 2007. Ann Thorac Surg. 2012;94(6):1870-1877. discussion 1877-9.
Pack QR, Priya A, Lagu T, et al. Development and validation of a predictive model for short- and medium-term hospital readmission following heart valve surgery. J Am Heart Assoc. 2016;5(9):e003544.
Sorajja P, Mack M, Vemulapalli S, et al. Initial experience with commercial transcatheter mitral valve repair in the United States. J Am Coll Cardiol. 2016;67(10):1129-1140.
Neuman MD, Wirtalla C, Werner RM. Association between skilled nursing facility quality indicators and hospital readmissions. JAMA. 2014;312(15):1542-1551.
Fernandes-Taylor S, Berg S, Gunter R, et al. Thirty-day readmission and mortality among Medicare beneficiaries discharged to skilled nursing facilities after vascular surgery. J Surg Res. 2018;221:196-203.
Kolte D, Kennedy KF, Shishehbor MH, et al. Thirty-day readmissions after endovascular or surgical therapy for critical limb ischemia: analysis of the 2013 to 2014 Nationwide readmissions databases. Circulation. 2017;136(2):167-176.
Henry L, Halpin L, Hunt S, Holmes SD, Ad N. Patient disposition and long-term outcomes after valve surgery in octogenarians. Ann Thorac Surg. 2012;94(3):744-750.